| Chromones: Privileged scaffold in anticancer drug discovery VM Patil, N Masand, S Verma, V Masand Chemical Biology & Drug Design 98 (5), 943-953, 2021 | 53 | 2021 |
| Target Based Drug Design-A Reality in Virtual Sphere S Verma, U Debnath, P Agarwal, K Srivastava, YS Prabhakar Current medicinal chemistry 22 (13), 1603-1630, 2015 | 38 | 2015 |
| Synthesis of 2, 3, 6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents S Sharma, M Saquib, S Verma, NN Mishra, PK Shukla, R Srivastava, ... European Journal of Medicinal Chemistry 83, 474-489, 2014 | 29 | 2014 |
| Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics U Debnath, S Verma, S Jain, SB Katti, YS Prabhakar Journal of computer-aided molecular design 27, 637-654, 2013 | 22 | 2013 |
| Prospective mode of action of Ivermectin: SARS-CoV-2 VM Patil, S Verma, N Masand European Journal of Medicinal Chemistry Reports 4, 100018, 2022 | 18 | 2022 |
| N-(7-Chloroquinolinyl-4-aminoalkyl)arylsulfonamides as antimalarial agents: rationale for the activity with reference to inhibition of hemozoin formation S Verma, S Pandey, P Agarwal, K Srivastava, P Verma, S Deshpande, ... RSC Adv 6 (30), 25584-25593, 2016 | 16 | 2016 |
| Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein S Verma, VM Patil, MK Gupta Drug Discovery Today 27 (10), 103312, 2022 | 15 | 2022 |
| Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds. PYS Dewaker V, Srivastava PN, Verma S J Biomol Struct Dyn, 2019 | 13 | 2019 |
| Topological and physicochemical characteristics of 1,2,3,4-Tetrahydroacridin- 9(10H)-ones and their antimalarial profiles: a composite insight to the structure-activity relation. BK Sharma, S Verma, YS Prabhakar Curr Comput Aided Drug Des 9 (3), 317-35, 2013 | 12 | 2013 |
| Synthesis, Biological Evaluation and Molecular Modeling Studies of New 2, 3‐Diheteroaryl Thiazolidin‐4‐Ones as NNRTI s U Debnath, S Verma, P Singh, K Rawat, SK Gupta, RK Tripathi, ... Chemical Biology & Drug Design 86 (5), 1285-1291, 2015 | 7 | 2015 |
| In Silico Exploration for New Antimalarials: Arylsulfonyloxy Acetimidamides as Prospective Agents S Verma, U Debnath, P Agarwal, K Srivastava, YS Prabhakar J Chem Inf Model, 2015 | 6 | 2015 |
| Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation V Dewaker, PN Srivastava, S Verma, AK Srivastava, YS Prabhakar Journal of Biomolecular Structure and Dynamics 40 (24), 13432-13455, 2022 | 4 | 2022 |
| Protein Informatics and Vaccine Development: Cancer Case Study S Verma, N Masand, RS Cheke, VM Patil Current Topics in Medicinal Chemistry 22 (26), 2207-2220, 2022 | 2 | 2022 |
| Identification of Adjacent NNRTI binding pocket in multi-mutated HIV1-RT enzyme model: An in silico study RF Kamil, U Debnath, S Verma, YS Prabhakar Current HIV Research 16 (2), 121-129, 2018 | 2 | 2018 |
| A review on recent synthetic routes and computational approaches for antibody drug conjugation developments used in anti-cancer therapy U Debnath, S Verma, J Patra, SK Mandal Journal of Molecular Structure 1256, 132524, 2022 | 1 | 2022 |
| Recent advances and structure-activity relationship studies of DPP-4 inhibitors as anti-diabetic agents S Singhal, VM Patil, S Verma, N Masand Bioorganic Chemistry, 107277, 2024 | | 2024 |
| Synthesis, ADME, Molecular Docking and Biological Evaluation of New 2-Aminobenzothiazloes U Agarwal, RK Tonk, K Sharma, R Bhutani, S Verma Current Bioactive Compounds 19 (9), 81-94, 2023 | | 2023 |
| β-Secretase as a Primary Drug Target of Alzheimer Disease: Function, Structure, and Inhibition S Verma, D Paramanick Deciphering Drug Targets for Alzheimer’s Disease, 95-109, 2023 | | 2023 |
| Chapter 12 - Rhomboid proteases leading to cancer: Structures, functions, and inhibition S Verma, R Kumar Cancer-leading proteases structure, function, and inhibition, 327- 527, 2020 | | 2020 |
Utsab Debnath, Ph.D.Associate Professor, School of Health Science & Technology, UPES - DehradunVerified email at ddn.upes.ac.in
